The transaction remains subject to regulatory approval in the United States. The companies are in advanced discussions with the US Dept. of Justice (DOJ), which includes the potential for required remedies. Inclusive of remedies required by the European Commission, collective potential remedies would represent an immaterial proportion of the total sales for the combined company and would not impact the US$180 million of net-cost synergies expected to be delivered by the end of the third year following completion.
As previously announced, the deal is expected to close May 15.